By Josh Beckerman

Provention Bio Inc. said the U.S. Food and Drug Administration approved the Biologics License Application for TZIELD as a treatment to delay the onset of Stage 3 type 1 diabetes in patients ages 8 and up with Stage 2 type 1 diabetes.

Shares were up 1 cent after hours st $8.25 before the stock was halted due to pending news.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

November 17, 2022 18:24 ET (23:24 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Provention Bio Charts.
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Provention Bio Charts.